临床药理学
观察研究
个性化医疗
风险分析(工程)
鉴定(生物学)
系统生物学
补语(音乐)
系统药理学
风险评估
药物开发
医疗保健
精密医学
临床实习
计算机科学
数据科学
药品
医学
生物信息学
药理学
生物
病理
政治学
基因
表型
互补
法学
家庭医学
植物
生物化学
计算机安全
作者
Lawrence J. Lesko,Songmao Zheng,Stephan Schmidt
摘要
Adverse drug events (ADEs) remain a universal problem in drug development, regulatory review, and clinical practice with a substantial financial burden on the global health-care system. Recent advances in molecular and “omics” technologies, along with online databases and bioinformatics, have enabled a more integrative approach to understanding drug-target (protein) interactions, both desirable and undesirable, within a biological system. This has led to the development of systems approaches to risk assessment in an attempt to complement and improve on contemporary observational and predictive strategies for assessing risk. Although still in an evolutionary phase, systems approaches have the potential to markedly advance our understanding of ADEs and ability to predict them. Systems approaches will also move personalized medicine forward by enabling better identification of individual and subgroup risk factors. Clinical Pharmacology & Therapeutics (2013); 93 5, 413–424. doi:10.1038/clpt.2013.29
科研通智能强力驱动
Strongly Powered by AbleSci AI